An interventional study of Device assisted high-dose therapy in Stroke, sponsored by Centre Hospitalier Universitaire Vaudois. Recruiting at 5 sites in Switzerland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Centre Hospitalier Universitaire Vaudois · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.
Among the 216 studies in Stroke with a site in Switzerland, this one is the 59th largest by planned enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2026, is one of 95 with no phase, reaches primary completion later than 38 of the 59 other live ones, and was the 202nd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Ecole Polytechnique Fédérale de Lausanne · Sites in Switzerland
Ages 18–70
School of Health Sciences Geneva · Sites in Switzerland
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
Prof. Dr. Jan Liman · Sites in Switzerland, Germany
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 37 · Phase 4 7
First in 1998; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 79 across the 147 interventional studies, 200 across the 69 observational. Of the 134 that completed or were terminated, 19 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 216 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire Vaudois is the lead sponsor of 208 studies on the registry; 48 are open to participants now.
Centre Hospitalier Universitaire Vaudois has 4 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
10 of the studies in Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
| NCT06466772University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT07444151School of Health Sciences GenevaPost-Stroke Fatigue Perception Study (ReFast) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 216 studies in Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
High-dose, high-intensity (HDHI) neurorehabilitation has shown promise for improving functional outcomes after acquired brain injury (ABI), yet its feasibility and impact across different stages of care and real-world clinical settings remain insufficiently understood.
The SwissNeuroRehab (SNR) initiative, bringing together Swiss rehabilitation centres to develop and evaluate innovative, technology-supported models of neurorehabilitation, provides the broader framework within which this study is conducted.
Within this framework, a structured HDHI therapy pathway supported by CE-marked digital neurorehabilitation tools has been developed for delivery across inpatient, outpatient, and home environments in Switzerland.
This multicentre, non-randomised interventional feasibility study evaluates the feasibility and preliminary clinical effects of implementing this HDHI rehabilitation pathway for adults with stroke in subacute and chronic stages. Participants will receive approximately 300 minutes per week of active, technology-supported training in addition to standard rehabilitation care, following an individually tailored pathway across settings. Standardised clinical assessments, patient-reported outcomes, documentation of rehabilitation procedures, and socioeconomic measures will be collected at baseline, discharge, and follow-up timepoints up to 12-15 months post-enrollment.
The primary aim of the study is to assess the feasibility of the HDHI intervention within routine rehabilitation workflows across multiple Swiss centres. Feasibility will be evaluated through (i) adherence to at least half of the weekly 300-minute Active Training Time target and (ii) patients' perceived feasibility and satisfaction with the program.
Secondary aims are to explore preliminary clinical and functional changes, patient-reported outcomes, and quantify socioeconomic impacts through dedicated surveys and cost data.
Findings from this study will (i) determine whether a structured HDHI rehabilitation pathway can be feasibly implemented across diverse clinical contexts, (ii) provide initial estimates of clinical and socioeconomic outcomes to support planning of future controlled trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a high-dose, high-intensity (HDHI) motor rehabilitation program supported by digital therapeutic devices, delivered across inpatient, outpatient and home-based settings.
Behavioral: Device assisted high-dose therapy
Participants undergo a high-dose, high-intensity (HDHI) neurorehabilitation program using CE-marked digital therapeutic devices (MindMotion GO, Izar). The intervention is tailored to individual motor rehabilitation needs and delivered across settings: during inpatient rehabilitation (4-6 weeks) and/or home-based outpatient care (8-12 weeks). Participants are expected to train actively for approximately one hour per day (5day week), supported by clinical staff and if applicable, caregivers.The intervention is supervised by clinical teams specifically trained in the HDHI protocol, who provide ongoing therapeutic support and monitor progress across settings.
Also known as: Device assisted high-dose neurorehabilitation
HDHI training adherence (Active Training Time, ATT)
The adherence to ≥150 minutes per week of Active Training Time (ATT), corresponding to at least half of the predefined weekly target of 300 minutes/week. ATT is derived from device-recorded active training logs and aggregated by calendar week during the intervention period. Weekly ATT is summarized across the intervention period to determine whether participants meet the predefined weekly adherence criterion.
Time frame: Weekly during the intervention period (up to 18 weeks)
Feasibility and satisfaction with the HDHI program (Program Feasibility and Satisfaction Questionnaire)
The perceived feasibility and patient satisfaction with the HDHI program, assessed using a study-specific Program Feasibility and Satisfaction Questionnaire consisting of 12 Likert-scale items covering accessibility/ease of use, pleasant content, empowerment capability, self-efficacy, alignment with clinical objectives, alignment with personal values and culture, environmental context, trust in the program, and perceived personal value. Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). A total score is calculated by summing item scores, with a minimum possible score of 12 and a maximum possible score of 60; higher scores indicate greater perceived feasibility and satisfaction.
Time frame: At discharge from the intervention and at follow-up assessments up to 15 months post-inclusion
Fugl-Meyer Assessment - Upper Extremity (FMA-UE)
Upper-limb motor impairment measured using the Fugl-Meyer Assessment for Upper Extremity (FMA-UE). The motor domain of the FMA-UE consists of 33 items assessing upper-limb motor function, with a total score ranging from 0 to 66; higher scores indicate better motor function and less motor impairment.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Action Research Arm Test (ARAT)
Upper-limb functional performance measured using the Action Research Arm Test (ARAT). The ARAT consists of 19 items across grasp, grip, pinch, and gross movement domains, with each item scored from 0 to 3, resulting in a total score ranging from 0 to 57; higher scores indicate better upper-limb functional performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Extended Barthel Index (eBI)
Activities of daily living performance measured using the Extended Barthel Index (eBI). The eBI assesses functional independence in activities of daily living using a 16-item scale, with a total score ranging from 0 to 64; higher scores indicate greater independence and better activities of daily living performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Functional Independence Measure (FIM)
Functional independence measured using the Functional Independence Measure (FIM). The FIM is an 18-item scale assessing independence in activities of daily living, with each item scored from 1 to 7, resulting in a total score ranging from 18 to 126; higher scores indicate greater functional independence.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Modified Rankin Scale (mRS)
Global disability measured using the Modified Rankin Scale (mRS). The mRS is a 7-point ordinal scale ranging from 0 (no symptoms) to 6 (death), used to assess the level of functional disability and dependence in daily activities; higher scores indicate greater disability and worse functional outcome.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Grip Strength - Hand Dynamometry
Grip strength of the affected hand measured using a Jamar hand dynamometer. Maximum voluntary grip strength is recorded in kilograms (kg), calculated as the mean of three trials; higher values indicate greater grip strength.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Mini Balance Evaluation Systems Test (Mini-BESTest)
Balance performance measured using the Mini Balance Evaluation Systems Test (Mini-BESTest). The Mini-BESTest consists of 14 items, each scored from 0 to 2, assessing dynamic balance across anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait, with a total score ranging from 0 to 28; higher scores indicate better balance performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
10-Meter Walk Test (10mWT)
Gait speed measured using the 10-Meter Walk Test (10mWT) performed at self-selected walking speed. Gait speed is calculated in meters per second (m/s); higher values indicate faster walking speed and better gait performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
6-Minute Walk Test (6MWT)
Gait endurance measured using the 6-Minute Walk Test (6MWT). Endurance is quantified as the total distance walked in meters during the 6-minute test period; higher values indicate greater walking endurance and better gait performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Timed Up and Go test (TUG)
Functional mobility measured using the Timed Up and Go test (TUG). Performance is quantified as the time required to stand up from a chair, walk 3 meters, turn, walk back, and sit down, measured in seconds (s); lower values indicate better functional mobility.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Five Times Sit-to-Stand test (5xSTS)
Lower-limb functional strength and balance measured using the Five Times Sit-to-Stand test (5xSTS). Performance is quantified as the time required to stand up from and sit down on a chair five times consecutively, measured in seconds (s); lower values indicate better lower-limb functional performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Patient Global Impression of Change (PGIC)
Participant's global perception of change in overall health status measured using the Patient Global Impression of Change (PGIC) scale. The PGIC is a 7-point ordinal scale ranging from 1 (very much worse) to 7 (very much improved); higher scores indicate greater perceived improvement.
Time frame: At discharge from the intervention and at follow-up assessments up to 15 months post-inclusion
Pain Visual Analog Scale (VAS)
Self-reported pain intensity measured using a Visual Analog Scale (VAS). Pain intensity is rated on a numeric scale ranging from 0 (no pain) to 100 (worst pain imaginable); higher scores indicate greater pain intensity.
Time frame: From baseline to follow-up assessments up to 12 months post-discharge
EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
Health-related quality of life measured using the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire. The EQ-5D-5L descriptive system assesses health status across five dimensions, each rated on five ordered levels (1 = no problems to 5 = extreme problems). Responses are combined to derive an EQ-5D-5L index score; higher index values indicate better health-related quality of life.
Time frame: From baseline to follow-up assessments up to 12 months post-discharge
PROMIS Global-10
Self-reported global physical and mental health status measured using the PROMIS Global Health (Global-10) questionnaire. The instrument yields two summary scores: Global Physical Health (GPH) raw score and Global Mental Health (GMH) raw score. Each summary score has a raw score range from 4 to 20; higher scores indicate better health status.
Time frame: From baseline to follow-up assessments up to 12 months post-discharge
Short Form Stroke Impact Scale (SF-SIS)
Stroke-specific impact on daily life and participation measured using the Short Form Stroke Impact Scale (SF-SIS). The SF-SIS is a patient-reported questionnaire assessing the perceived impact of stroke on physical function, activities, cognition, communication, emotion, and participation using ordered response categories; higher scores indicate better function and less perceived impact of stroke.
Time frame: From baseline to follow-up assessments up to 12 months post-discharge
Falls and sleep-related outcomes (modified questionnaire)
Self-reported occurrence of falls and sleep-related characteristics assessed using a study-specific modified falls and sleep questionnaire. Falls outcomes include the number of falls, number of falls resulting in injury, and number of falls requiring hospitalisation during the preceding month. Sleep-related outcomes include self-reported interference of sleep problems with daily functioning, assessed using an ordinal response scale, where higher ratings indicate greater interference.
Time frame: From baseline to follow-up assessments up to 12 months post-discharge
Behavioral Risk Factor Surveillance System (BRFSS) items
Health-related risk and well-being characteristics assessed using selected items from the Behavioral Risk Factor Surveillance System (BRFSS). Outcomes include the number of days in the past 30 days during which participants report poor physical health, poor mental health, and activity limitation due to poor physical or mental health, recorded as counts of days (0-30). Higher values indicate a greater number of unhealthy days.
Time frame: From baseline to follow-up assessments up to 12 months post-discharge
Socio-Economic Status and Health Resource Use
Socio-economic characteristics and health resource use assessed using a study-specific structured socio-economic questionnaire and rehabilitation-related resource use data. Variables include employment status, living situation, support needs, and use of rehabilitation and healthcare services, reported descriptively.
Time frame: Socio-economic questionnaire: From baseline to follow-up assessments up to 15 months post-inclusion Administrative health resource use data: Annually, for the duration of study participation
Standard of Care and Exercise Exposure
Exposure to standard rehabilitation care and additional physical exercise assessed using a study-specific structured questionnaire and/or exercise diary. Variables include the type, frequency, and duration of rehabilitation and physical activities performed outside the HDHI program, reported descriptively.
Time frame: During study participation, assessed retrospectively at discharge and follow-up assessments up to 15 months post-inclusion
Program delivery feasibility
Feasibility of HDHI program delivery assessed using program-specific documentation, including enrollment records, completion status, and discharge documentation. Feasibility outcomes include the number and proportion of participants who initiate the program, complete the intervention, and discontinue prematurely, reported descriptively.
Time frame: From program initiation through completion of the intervention (up to 18 weeks)
Training dose delivery
Training dose delivery assessed using device-recorded session logs. Outcomes include total active training time, number of completed sessions, and distribution of training across modalities, summarized descriptively over the intervention period.
Time frame: During the intervention period (up to 18 weeks)
Systolic Blood Pressure
Systolic blood pressure measured in millimeters of mercury (mmHg) using standard clinical procedures.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion.
Diastolic blood pressure
Diastolic blood pressure measured in millimeters of mercury (mmHg) using standard clinical procedures.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Heart Rate
Heart rate measured in beats per minute (bpm) using standard clinical procedures.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Peripheral oxygen saturation (SpO₂)
Peripheral oxygen saturation measured as percentage of hemoglobin oxygen saturation (%) using pulse oximetry.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Digit Span Forward
Memory domain: Verbal short-term memory and attention span, assessed using the Digit Span Forward task. Performance is defined as the maximum correctly recalled digit sequence length; Performance is reported as a standardized score derived from test norms (e.g., T-score).
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Digit Span Backward
Working memory domain: Verbal working memory involving mental manipulation, assessed using the Digit Span Backward task. Performance is reported as a standardized score derived from test norms (e.g., T-score), with higher scores indicating better working memory performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Block Span (Corsi Block-Tapping Test)
Memory domain: Visuospatial short-term memory, assessed using the Block Span (Corsi Block-Tapping) Test. Performance is reported as a standardized score based on normative data, with higher scores indicating better visuospatial working memory.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Trail Making Test Part A (TMT-A)
Non-lateralized attention (processing speed domain): visual scanning and psychomotor processing speed assessed using the Trail Making Test Part A. Performance is reported using standardized scores based on completion time, with higher scores indicating better performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Trail Making Test Part B(TMT-B)
Executive function domain: cognitive flexibility and set shifting assessed using the Trail Making Test Part B under speeded visuomotor conditions. Performance is reported using standardized scores, with higher scores indicating better cognitive flexibility.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Color Trails Test 1
Non-lateralized attention (processing speed domain): visual scanning and psychomotor processing speed assessed using the Color Trails Test Part 1. The Color Trails Test is used as a language-reduced alternative to the Trail Making Test Part A in participants with aphasia or limited literacy. Performance is reported as a standardized score derived from test norms, with higher scores indicating better performance.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Color Trails Test 2
Executive function domain: cognitive flexibility and set shifting assessed using the Color Trails Test Part 2 under speeded visuomotor conditions. The Color Trails Test is used as a language-reduced alternative to the Trail Making Test Part B in participants with aphasia or limited literacy. Performance is reported as a standardized score derived from test norms, with higher scores indicating better cognitive flexibility.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Five-Point Test (5PT)
Executive function domain: figural fluency assessed using the Five-Point Test, reflecting nonverbal generative fluency and self-monitoring. Performance is reported as a standardized score derived from the number of unique designs produced, with higher scores indicating better figural fluency.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Phonemic Fluency
Executive function domain: phonemic verbal fluency assessed by the ability to generate words according to phonemic constraints within a fixed time period. Performance reflects executive control of lexical retrieval and self-monitoring and is reported as a standardized score, with higher scores indicating better phonemic fluency.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Semantic Fluency
Executive function domain: semantic verbal fluency assessed by the ability to generate words within a semantic category during a fixed time period. Performance primarily reflects semantic memory retrieval supported by executive control processes and is reported as a standardized score, with higher scores indicating better semantic fluency.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Stroop Test
Executive function domain: interference control assessed using the Stroop Color-Word Test. Performance reflects the ability to resolve cognitive interference under competing stimulus conditions and is reported as a standardized score derived from response time and error measures, with higher scores indicating better interference control.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
TAP Go/No-Go
Executive function domain: motor response inhibition assessed using the Go/No-Go subtest of the Test of Attentional Performance (TAP). This task is used as a language-independent alternative to the Stroop test in participants with aphasia or limited literacy. Performance is reported as a standardized score derived from error rates and reaction time measures, with higher scores indicating better response inhibition.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
TAP Alertness
Non-lateralized attention domain: tonic alertness assessed using the Alertness subtest of the Test of Attentional Performance (TAP). Performance reflects baseline response readiness and is reported as a standardized score derived from reaction time measures, with higher scores indicating better alertness.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
TAP Divided Attention
Non-lateralized attention domain: divided attention assessed using the Divided Attention subtest of the Test of Attentional Performance (TAP). Performance reflects the ability to allocate attentional resources across concurrent tasks and is reported as a standardized score derived from reaction time and/or error measures, with higher scores indicating better divided attention.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
TAP Shift of Focus
Executive-attentional domain: attentional flexibility assessed using the Shift of Focus (Flexibility) subtest of the Test of Attentional Performance (TAP). Performance reflects the ability to shift attentional focus between task-relevant stimuli and is reported as a standardized score derived from reaction time and/or error measures, with higher scores indicating better attentional flexibility.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Apples Test
Lateralized attention domain: visuospatial attention bias assessed using the Apples Test, which dissociates egocentric and allocentric spatial attention deficits. Performance is reported using standardized asymmetry indices derived from cancellation accuracy, with greater symmetry indicating better spatial attention.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Working Memory Questionnaire (WMQ)
Working memory domain: Self-reported working-memory-related difficulties in everyday functioning assessed using a standardized Working Memory Questionnaire. Scores are reported according to the questionnaire scoring manual, with higher scores indicating greater perceived working-memory difficulties.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Hospital Anxiety and Depression Scale (HADS)
Depression and anxiety symptoms assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire with two 7-item subscales (Anxiety and Depression). Each item is scored 0-3; subscale scores range 0-21 and total score ranges 0-42, with higher scores indicating greater symptom severity.
Time frame: From Baseline to follow-up assessments up to 15 months post-inclusion
Fatigue Scale for Motor and Cognitive Functions (FSMC)
Fatigue assessed using the Fatigue Scale for Motor and Cognitive Functions (FSMC), a 20-item self-report questionnaire comprising motor and cognitive fatigue subscales. Items are rated on an ordered response scale, and subscale and total scores are calculated according to the scoring manual, with higher scores indicating greater fatigue severity.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Modified Ashworth Scale (MAS)
Spasticity assessed using the Modified Ashworth Scale (MAS) for specified joints (shoulder, elbow, wrist, hip, knee, ankle, fingers). MAS is scored on an ordinal scale (0, 1, 1+, 2, 3, 4), where higher scores indicate greater resistance to passive movement (greater spasticity).
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion.
Muscle Strength Testing (MST)
Voluntary muscle strength assessed using manual Muscle Strength Testing (MST) of upper and lower limbs according to standardized site procedures. Muscle strength is recorded as ordinal strength grades for predefined muscle groups of the upper and lower extremities, with higher grades indicating greater muscle strength.
Time frame: From baseline to follow-up assessments up to 15 months post-inclusion
Plan to share: No
Start is estimated for Feb 2026; primary completion for May 2028, 27 months later.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 27 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire Vaudois →